Operating
Stock-Based Comp
Revolution Medicines, Inc. Stock-Based Comp increased by 159.1% to $87.30M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 248.0%, from $25.08M to $87.30M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows an upward trend with a 54.6% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2018
Last reportedQ1 2026May 6, 2026
How to read this metric
Increasing levels may indicate a focus on talent retention but can also signal potential shareholder dilution.
Detailed definition
This represents the value of equity-based awards granted to employees as part of their total compensation package. Since...
Peer comparison
Standard across large-cap corporations; varies based on corporate compensation philosophy.
Metric ID:
stock_based_compensationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $5.31M | $5.83M | $6.20M | $6.64M | $8.10M | $8.14M | $8.32M | $9.70M | $12.98M | $13.67M | $25.43M | $16.21M | $19.78M | $20.78M | $22.44M | $25.08M | $28.83M | $30.78M | $33.70M | $87.30M |
| QoQ Change | — | +9.7% | +6.3% | +7.2% | +21.9% | +0.5% | +2.2% | +16.6% | +33.8% | +5.3% | +86.1% | -36.3% | +22.0% | +5.1% | +8.0% | +11.8% | +14.9% | +6.8% | +9.5% | +159.1% |
| YoY Change | — | — | — | — | +52.4% | +39.7% | +34.2% | +46.0% | +60.3% | +67.9% | +205.8% | +67.1% | +52.3% | +52.0% | -11.8% | +54.8% | +45.8% | +48.2% | +50.2% | +248.0% |
Range$5.31M – $87.30M
CAGR+80.3%
Avg YoY Growth+69.6%
Median YoY Growth+52.2%
Current Streak8 quarters growth
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is Revolution Medicines, Inc.'s stock-based comp?
- Revolution Medicines, Inc. (RVMD) reported stock-based comp of $87.30M in Q1 2026.
- How has Revolution Medicines, Inc.'s stock-based comp changed year-over-year?
- Revolution Medicines, Inc.'s stock-based comp increased by 248.0% year-over-year, from $25.08M to $87.30M.
- What is the long-term trend for Revolution Medicines, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), Revolution Medicines, Inc.'s stock-based comp has grown at a 54.6% compound annual growth rate (CAGR), from $20.72M to $118.39M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock instead of cash.